SARS-CoV-2 spike antibodies cross-react with dengue virus and enhance infection in vitro and in vivo
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (Rapid Reviews Infectious Diseases)
Abstract
The presence of non-neutralizing antibodies of any dengue serotype increases the severity of subsequent infection by other dengue serotypes. During the SARS-CoV-2 pandemic, the number of symptomatic dengue cases increased in India. We found that antibodies isolated from convalescent plasma from COVID-19 patients enhances DENV2 infection in vitro . CR3022, an antibody against the SARS-CoV-2 spike protein, also elevated DENV2 infection in vitro . In silico protein–protein interactions between spike antibodies and the DENV2 E-protein revealed significant interactions. Likewise, few monoclonal/polyclonal antibodies against SARS-CoV-2 have shown increased dengue infection in vitro . Importantly, AG129 mice infected with SARS-CoV-2 three weeks prior to DENV2 infection showed elevated dengue pathogenesis. This highlights the possibility of elevated infection and symptomatic dengue disease in COVID-19 survivors.
Article activity feed
-
SARS-CoV-2 antibodies cross-react and enhance dengue infection www.biorxiv.org/content/10.1...
-
-
-
If it's all covid sequelae, the only unexpected one would be malaria. But then again, look at this paper about dengue (in preprint for 2 years already, beware): SARS-CoV-2 antibodies cross-react and enhance dengue infection www.biorxiv.org/content/10.1...
-
-
That is the most absurd thing I have heard today. Do they not understand how ADE works with dengue virus? Also, I feel like this preprint might explain it: www.biorxiv.org/content/10.1...
-
It's always worth remembering that, fundamentally, 'immunity debt' is a political term, a convenient and media-friendly phrase to explain away what is much more likely to be pathogen-pathogen interaction. A representative example (SARS-CoV-2 & DENV-2): www.biorxiv.org/content/10.1...
-
-
-
-
-
-
-
Going to make use of the fact that there still isn't huge amount of engagement here to ask what you think of this preprint? Obvs small sample, but may have big implications for vaccination strategy, and i was wondering if there are any red flags i'm overlooking? www.biorxiv.org/content/10.1...
-
This could explain why we see higher severity in Dengue worldwide: prior Covid infections can lead to higher severity of Dengue infections. "... anti-SARS-CoV-2 antibodies can cross-react with DENV-2 and can enhance its infection through ADE." www.biorxiv.org/content/10.1...
-
A bit desperate to find faults with this preprint. #virosky www.biorxiv.org/content/10.1...
-
ADE (Antibody Dependent Enhancement) effect after sars2 infection for another virus, dengue. You can see what sars2 does. It helps other viruses, it makes them more deleterious, it changes their processes because it harms the human biological make-up.
-
Der Link zur Studie: www.biorxiv.org/content/10.1... #COVID19 #SARSCoV2 #Dengue #Coronavirus #CovidIsNotOver #MaskUp #CleanAir #Ventilation
-
#Preprint "This study is the first to demonstrate that anti-SARS-CoV-2 Antibodies can cross-react with DENV-2 and can enhance its infection through ADE." Nicht nett für die Regionen, in welchen Dengue endemisch ist www.biorxiv.org/content/10.1...
-
SARS-CoV-2 antibodies cross-react and enhance dengue infection https://www.biorxiv.org/content/10.1101/2023.10.09.557914v1
-
SARS-CoV-2 antibodies cross-react and enhance dengue infection https://www.biorxiv.org/content/10.1101/2023.10.09.557914v1
-
